FINEARTS-HF 试验:射血分数轻度降低或保留心衰患者的死亡模式
FINEARTS-HF 预设二次分析纳入 6001 例 EF≥40% 心衰患者,中位随访 32 个月内 1013 例死亡,心血管死亡占 49.6%,其中猝死 42.8%、心衰死亡 32.4%。EF<50% 者全因、心血管及猝死比例更高;非奈利酮未显著降低任何 EF 亚组的死亡或病因特异性死亡。
要点
- HFmrEF/HFpEF 死亡者中近半数为心血管死亡,猝死是最常见心血管死因。
- EF<50% 患者全因、心血管和猝死比例高于 EF≥50% 者。
- 非奈利酮未显著降低全因或病因特异性死亡,试验可能把握度不足。
核心结论
- 在 HFmrEF/HFpEF 患者中,EF<50% 者全因和心血管死亡比例更高主要归因于猝死比例更高。
- 非奈利酮未显示对心血管死亡或病因特异性死亡的显著治疗效应,但试验对这些结局可能把握度不足。
研究设计与样本
- FINEARTS-HF 随机临床试验的预设二次分析,纳入 6001 例 EF≥40% 的心衰患者,随机接受非奈利酮或安慰剂。
- 按基线 EF 分类(<50%、≥50-<60%、≥60%)分析死亡模式,并用 Cox 回归评估治疗对病因特异性死亡的影响。
主要发现
- 中位随访 32 个月,1013 例(16.9%)死亡,其中 502 例(49.6%)为心血管死亡,368 例(36.3%)为非心血管死亡,143 例(14.1%)原因未定。
- 心血管死亡中,215 例(42.8%)为猝死,163 例(32.4%)为心衰死亡,48 例(9.6%)为卒中,25 例(5.0%)为心肌梗死,51 例(10.2%)为其他心血管原因。
- EF<50% 者全因、心血管及猝死比例更高;心衰死亡比例在各 EF 分类间相似,心肌梗死、卒中及其他心血管死亡比例在各 EF 分类均较低。
- 非奈利酮与安慰剂相比,在任何 EF 分类中均未显著降低死亡或病因特异性死亡。
临床怎么用
- 对 HFmrEF/HFpEF 患者评估死亡风险时,应关注 EF<50% 者猝死风险较高。
- 非奈利酮在该人群中未显示明确的死亡获益,不能以降低死亡为主要目的使用。
局限性
- 该分析为预设二次分析,试验对死亡结局可能把握度不足。
- 死亡模式分析为描述性,未报告各 EF 分类间比较的统计检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The mode of death in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) remains poorly understood and may vary by EF. OBJECTIVE: To evaluate the mode of death according to EF and the treatment effect of finerenone on cause-specific mortality in patients with HFmrEF/HFpEF. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial, which evaluated clinical outcomes in 6001 patients with HF and EF greater than or equal to 40% randomly assigned to finerenone or placebo. The mode of death in relation to baseline EF categories (<50%, ≥50-<60%, and ≥60%) was examined, and the effect of randomized treatment on cause-specific death in Cox regression models was assessed. Data analysis was conducted between September 2024 and January 2025. INTERVENTIONS: Finerenone vs placebo. MAIN OUTCOMES AND MEASURES: Mode of death as centrally adjudicated by a clinical end points committee. RESULTS: Of 1013 patients (16.9%; median [IQR] age, 76 [69-82] years; 594 male [58.6%]) who died during median (IQR) follow-up of 32 (23-36) months, mode of death was ascribed to cardiovascular causes in 502 (49.6%), noncardiovascular causes in 368 (36.3%), and undetermined cause in 143 (14.1%). Of cardiovascular deaths, 215 (42.8%) were due to sudden death, 163 (32.4%) to HF, 48 (9.6%) to stroke, 25 (5.0%) to myocardial infarction, and 51 (10.2%) to other cardiovascular causes. The proportion of all-cause, cardiovascular, and sudden death was higher in those with EF less than 50%. The proportion of deaths related to HF was similar across EF categories, and the proportion of deaths due to myocardial infarction, stroke, and other cardiovascular causes was low regardless of EF. Randomization to finerenone did not significantly reduce death or cause-specific death compared with placebo in any EF category. CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF/HFpEF in the FINEARTS-HF randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with EF less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.
引用
- Desai AS, Jhund PS, Vaduganathan M, et al. Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40159247. doi:10.1001/jamacardio.2025.0860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。